Lv1
44 积分 2023-03-06 加入
Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis
8小时前
已完结
Targeting Lung Cancer with Precision: The ADC Therapeutic Revolution
19天前
已完结
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
1个月前
已完结
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
1个月前
已完结
Treatment of NSCLC after chemoimmunotherapy - are we making headway?
1个月前
已完结
Final analysis results and patient-reported outcomes from DESTINY-Lung02—a dose-blinded, randomized, phase 2 study of trastuzumab deruxtecan in patients with HER2-mutant metastatic non–small cell lung cancer
2个月前
已完结
Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia
2个月前
已完结
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer
2个月前
已完结
Ivonescimab in advanced NSCLC: is progression-free survival enough, or are overall survival data also needed?
3个月前
已完结
The evolving immuno-angiogenic paradigm in NSCLC: lessons from ivonescimab
3个月前
已完结
皖公网安备34019202002308
